These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
288 related articles for article (PubMed ID: 37389109)
1. Role of neoadjuvant therapy for nonmetastatic pancreatic cancer: Current evidence and future perspectives. Cassese G; Han HS; Yoon YS; Lee JS; Lee B; Cubisino A; Panaro F; Troisi RI World J Gastrointest Oncol; 2023 Jun; 15(6):911-924. PubMed ID: 37389109 [TBL] [Abstract][Full Text] [Related]
2. Treatment of pancreatic cancer-neoadjuvant treatment in resectable pancreatic cancer (PDAC). Seufferlein T; Ettrich TJ Transl Gastroenterol Hepatol; 2019; 4():21. PubMed ID: 30976724 [TBL] [Abstract][Full Text] [Related]
3. Advances and Remaining Challenges in the Treatment for Borderline Resectable and Locally Advanced Pancreatic Ductal Adenocarcinoma. Sulciner ML; Ashley SW; Molina G J Clin Med; 2022 Aug; 11(16):. PubMed ID: 36013111 [TBL] [Abstract][Full Text] [Related]
4. Opinions and use of neoadjuvant therapy for resectable, borderline resectable, and locally advanced pancreatic cancer: international survey and case-vignette study. Heinrich S; Besselink M; Moehler M; van Laethem JL; Ducreux M; Grimminger P; Mittler J; Lang H; Lutz MP; Lesurtel M; BMC Cancer; 2019 Jul; 19(1):675. PubMed ID: 31288786 [TBL] [Abstract][Full Text] [Related]
5. Neoadjuvant Therapy for Resectable Pancreatic Cancer: An Evolving Paradigm Shift. Chawla A; Ferrone CR Front Oncol; 2019; 9():1085. PubMed ID: 31681614 [TBL] [Abstract][Full Text] [Related]
6. Neoadjuvant Treatment in Pancreatic Cancer. Oba A; Ho F; Bao QR; Al-Musawi MH; Schulick RD; Del Chiaro M Front Oncol; 2020; 10():245. PubMed ID: 32185128 [TBL] [Abstract][Full Text] [Related]
7. Conversion Surgery for Pancreatic Cancer-The Impact of Neoadjuvant Treatment. Klaiber U; Hackert T Front Oncol; 2019; 9():1501. PubMed ID: 31993372 [TBL] [Abstract][Full Text] [Related]
8. Advances in neoadjuvant therapy for resectable pancreatic cancer over the past two decades. Taboada AGM; Lominchar PL; Roman LM; García-Alfonso P; Martin AJM; Rodriguez JAB; Pascual JMA Ann Hepatobiliary Pancreat Surg; 2021 May; 25(2):179-191. PubMed ID: 34053920 [TBL] [Abstract][Full Text] [Related]
9. Neoadjuvant therapy in pancreatic cancer: an emerging strategy. Bittoni A; Santoni M; Lanese A; Pellei C; Andrikou K; Stefano C Gastroenterol Res Pract; 2014; 2014():183852. PubMed ID: 25101123 [TBL] [Abstract][Full Text] [Related]
10. Neoadjuvant Treatment for Pancreatic Cancer. Raufi AG; Manji GA; Chabot JA; Bates SE Semin Oncol; 2019 Feb; 46(1):19-27. PubMed ID: 30630600 [TBL] [Abstract][Full Text] [Related]
11. Randomized phase II study of gemcitabine and S-1 combination therapy versus gemcitabine and nanoparticle albumin-bound paclitaxel combination therapy as neoadjuvant chemotherapy for resectable/borderline resectable pancreatic ductal adenocarcinoma (PDAC-GS/GA-rP2, CSGO-HBP-015). Yamada D; Kobayashi S; Takahashi H; Akita H; Yamada T; Asaoka T; Shimizu J; Takeda Y; Yokoyama S; Tsujie M; Tomokuni A; Tanemura M; Morimoto O; Murakami M; Kim Y; Nakahira S; Hama N; Sugimoto K; Hashimoto K; Doki Y; Eguchi H Trials; 2021 Aug; 22(1):568. PubMed ID: 34446057 [TBL] [Abstract][Full Text] [Related]
12. Neoadjuvant Chemotherapy in Pancreatic Cancer: An Appraisal of the Current High-Level Evidence. Müller PC; Frey MC; Ruzza CM; Nickel F; Jost C; Gwerder C; Hackert T; Z'graggen K; Kessler U Pharmacology; 2021; 106(3-4):143-153. PubMed ID: 32966993 [TBL] [Abstract][Full Text] [Related]
13. Pancreatic Cancer: A Review. Park W; Chawla A; O'Reilly EM JAMA; 2021 Sep; 326(9):851-862. PubMed ID: 34547082 [TBL] [Abstract][Full Text] [Related]
14. Clinical challenges associated with utility of neoadjuvant treatment in patients with pancreatic ductal adenocarcinoma. Gray S; de Liguori Carino N; Radhakrishna G; Lamarca A; Hubner RA; Valle JW; McNamara MG Eur J Surg Oncol; 2022 Jun; 48(6):1198-1208. PubMed ID: 35264307 [TBL] [Abstract][Full Text] [Related]
15. REDISCOVER guidelines for borderline-resectable and locally advanced pancreatic cancer: management algorithm, unanswered questions, and future perspectives. Boggi U; Kauffmann EF; Napoli N; Barreto SG; Besselink MG; Fusai GK; Hackert T; Hilal MA; Marchegiani G; Salvia R; Shrikhande SV; Truty M; Werner J; Wolfgang C; Bannone E; Capretti G; Cattelani A; Coppola A; Cucchetti A; De Sio D; Di Dato A; Di Meo G; Fiorillo C; Gianfaldoni C; Ginesini M; Hidalgo Salinas C; Lai Q; Miccoli M; Montorsi R; Pagnanelli M; Poli A; Ricci C; Sucameli F; Tamburrino D; Viti V; Cameron J; Clavien PA; Asbun HJ; Updates Surg; 2024 Apr; ():. PubMed ID: 38684573 [TBL] [Abstract][Full Text] [Related]
16. Borderline Resectable Pancreatic Cancer: Challenges for Clinical Management. Fawaz A; Abdel-Rahman O Cancer Manag Res; 2022; 14():3589-3598. PubMed ID: 36597515 [TBL] [Abstract][Full Text] [Related]
18. [Neoadjuvant treatment of primarily resectable and borderline resectable pancreatic cancer]. Scheufele F; Friess H Chirurg; 2020 May; 91(5):391-395. PubMed ID: 31965198 [TBL] [Abstract][Full Text] [Related]
19. Neoadjuvant Treatment in Resectable Pancreatic Cancer. Is It Time for Pushing on It? Vivarelli M; Mocchegiani F; Nicolini D; Vecchi A; Conte G; Dalla Bona E; Rossi R; Benedetti Cacciaguerra A Front Oncol; 2022; 12():914203. PubMed ID: 35712487 [TBL] [Abstract][Full Text] [Related]